Status
Conditions
About
Post sphinterotomy-bleeding (PSB) occurs in 1-2 % of Endosocpic Retrograde Cholangiopancreaticography (ERCP) and usually needs no blood transfusion after endoscopic therapy but can be life-threatening in some rare cases.
There are no prospective comparative studies concerning the endoscopic treatment of PSB due to the rarity of the incident.
Insertion of an endoprosthesis in the common bile duct may be more effective than Epinephrin-injection into the papilla which is the therapy of first choice.
A retrospective single centre analysis on both used methods over a study period of 16 years shall be performed.
Full description
Post sphinterotomy-bleeding (PSB) occurs in 1-2 % of Endosocpic Retrograde Cholangiopancreaticography (ERCP) and usually needs no blood transfusion after endoscopic therapy but can be life-threatening in some rare cases.
The increasing use of antiplatelet and/or anticoagulant therapies enhances the risk of PSB.
There are no prospective comparative studies concerning the endoscopic treatment of PSB due to the rarity of the incident.
Insertion of an endoprosthesis in the common bile duct may be more effective than Epinephrin-injection into the papilla which is the therapy of first choice.
A retrospective single centre analysis on both used methods over a study period of 16 years shall be performed.
In detail, clinical success and safety of the procedure, re-bleeding rate, number of re-interventions and days of hospital stay will be analysed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
100 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal